Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. TLTFF


Primary Symbol: V.TLT

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Next NR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1253)
•••
Comment by CancerSlayeron Nov 21, 2024 7:23pm
164 Views
Post# 36325025

RE:RE:RE:Next NR

RE:RE:RE:Next NR
DJDawg wrote:
All the good discussion about the bladder study makes me want to iterate that TLT is not a one drug and one indication company.

IV Ruvidar (Rutherrin) shows great promise for solid and liquid tumours
Ruvidar has antiviral properties that are potent and only just starting to be understood
Ruvidar may have a role in vaccine development (Manitoba work ongoing)

Those multiple avenues are a nice way of de-risking things.

I look forward to good updates in the coming 1-2 months.


In terms of de-risking, it's nice to also have the competition do some of the dirty work & lend us a hand by either underperforming &/or carrying excessive toxicity, all the while requiring an excessive number/duration of treatments.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities